Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + L-asparaginase + PEG-L-asparaginase + Erwinia asparaginase
- Development stage
- Unknown
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
This is a combination of chemotherapy agents used primarily in the treatment of acute lymphoblastic leukemia (ALL) and lymphoma. The combination includes: - Doxorubicin: An anthracycline antibiotic that intercalates with DNA and inhibits topoisomerase II, preventing DNA replication and transcription. - L-asparaginase: An enzyme that depletes asparagine, an amino acid essential for leukemic cell survival. - PEG-L-asparaginase (pegaspargase): A modified form of L-asparaginase with polyethylene glycol, which extends its half-life and reduces immunogenicity. - Erwinia asparaginase: An alternative form of asparaginase derived from Erwinia chrysanthemi, used in patients who develop hypersensitivity to E. coli-derived asparaginase. This combination has shown synergistic effects in cancer treatment, with studies indicating improved progression-free survival compared to traditional protocols.
- Other names
- TOTXV regimenTotal Therapy Study XV regimen
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + L-asparaginase + PEG-L-asparaginase + Erwinia asparaginase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + L-asparaginase + PEG-L-asparaginase + Erwinia asparaginase.